Humira Market Report: Market Size & Forecast 2026

The global Humira market encompasses sales of adalimumab-reference product and its biosimilar equivalents across multiple therapeutic indications. Following the loss of primary patent exclusivity in the United States in 2023 and subsequent biosimilar launches, the market has entered a transitional phase characterized by rapid biosimilar uptake alongside the reference product's authorized-generic strategy. Healthcare spending on inflammatory diseases, combined with expanding access in emerging markets, continues to underpin a market measured in the tens of billions of dollars.

• •Valued at approximately $9.61 billion in 2025, reflecting a market at the midpoint of its biosimilar transition
• •Therapy class: TNF-alpha inhibitor biologic treating autoimmune and inflammatory conditions
• •Original product developed by AbbVie; biosimilar entry accelerating across US, EU, and select Asian markets

A primary growth driver is the global prevalence of autoimmune disorders, which continues to rise alongside aging populations and improved diagnostic rates. The declining cost of biosimilars is expanding access to adalimumab-based therapies in middle-income countries that previously faced prohibitive pricing for the reference product. Furthermore, healthcare system policies promoting biosimilar substitution and formulary inclusion in markets such as Europe and Canada are structurally supporting volume-based market expansion even as per-unit prices decline.

• •Rising global prevalence of rheumatoid arthritis, Crohn's disease, plaque psoriasis, and related autoimmune conditions
• •Biosimilar cost reductions expanding patient access in emerging and middle-income healthcare markets
• •Policy frameworks in the EU, Canada, and select APAC markets encouraging biosimilar adoption through tender systems and interchangeability rules

By product type, the market is increasingly bifurcated between the reference product and a growing biosimilar segment, with biosimilars projected to capture a substantial and rising share over the forecast horizon. Regionally, North America remains the largest market driven by high diagnosis rates and extensive formulary coverage, while Europe constitutes a significant second market where biosimilar penetration rates are among the highest globally. The Asia-Pacific region is the fastest-growing geographic segment, propelled by improving healthcare infrastructure, rising disease awareness, and aggressive pricing strategies from biosimilar manufacturers seeking market share.

• •North America leads in absolute market value; Europe leads in biosimilar adoption penetration rates
• •Asia-Pacific emerging as the fastest-growing regional market due to expanding access and manufacturing capacity
• •Rheumatology and gastroenterology represent the largest therapeutic application segments within the market

What are the recent trends and outlook?

Looking ahead, the market is expected to experience continued volume-driven growth offset by per-unit price compression as biosimilar competition matures. Biobetter and high-concentration formulation innovations may create differentiated product tiers, while subcutaneous delivery advancements could improve patient adherence and expand addressable populations. Regulatory harmonization efforts, particularly in Latin America and Southeast Asia, are likely to accelerate biosimilar entry timelines in those regions, further reshaping global market dynamics through the end of the decade.

• •Biosimilar market projected to grow substantially faster than the overall adalimumab market, with segment-level CAGRs in the mid-to-high twenties
• •AbbVie's strategy of authorized generics and combination product bundling designed to retain physician and payer relationships through patent expiry
• •Emerging biobetter formulations and next-generation TNF inhibitors posing potential medium-term competitive headwinds